GnRH analogues in the treatment of uterine fibroids.

@article{Golan1996GnRHAI,
  title={GnRH analogues in the treatment of uterine fibroids.},
  author={Abraham Golan},
  journal={Human reproduction},
  year={1996},
  volume={11 Suppl 3},
  pages={
          33-41
        }
}
  • A. Golan
  • Published 1 November 1996
  • Medicine
  • Human reproduction
It is now known that gonadotrophin-releasing hormone analogues (GnRHa) are extremely efficient at reducing uterine fibroid volume and reversing the related symptomatology. However, the fibroids tend to return to their pretreatment size about 6 months after discontinuing treatment. GnRHa treatment cannot be continued indefinitely due to its potential complications and high cost. It is therefore proposed that GnRHa treatment should be phase one of a two-phase treatment plan for uterine fibroids… 
View on PubMed
academic.oup.com
49 Citations
Highly Influential Citations
1
Background Citations
18

49 Citations

Citation Type

Citation Type

Gonadotrophin hormone-releasing hormone analogue treatment of fibroids.
  • R. Shaw
  • Medicine, Biology
    Bailliere's clinical obstetrics and gynaecology
  • 1998
Current approaches to overcome the side effects of GnRH analogs in the treatment of patients with uterine fibroids.
TLDR
Results regarding the efficacy of new-generation oral GnRH-antagonists, such as elagolix, relugolix and linzagolix are promising and offer potential prospect for the future therapy of UFs, however, these antagonists must be combined with hormonal Add-back therapy to minimize the resultant hypoestrogenic side effects such as bone loss.
Peran GnRH agonis
TLDR
GnRH agonists halt the growth and reduce the size of an endometriosis, therefore, they can be used in patients with precocious puberty and premenstrual syndrome and the combination of exogenous gonadotropin plus a GnRH agonist used in vitro fertilization is associated with increased pregnancy rate as compared with the use of Gonadotropins without a Gn RH agonist.
GnRH Analogues and Uterine Leiomyomas
TLDR
The hormone add-back therapy moderated the influence of GnRHa on cell proliferation and completely blocked a decrease in size of leiomyomas in the authors' patients.
Uterine Fibroids
TLDR
Although the current armamentarium of Food and Drug Administration-approved medical therapies is limited, there are medications approved for use in heavy menstrual bleeding that can be used for the medical management of fibroids.
Regression of endometrial hyperplasia after treatment with the gonadotrophin-releasing hormone analogue triptorelin: a prospective study.
TLDR
It seems, therefore, that in cases of endometrial hyperplasia without atypia, the administration of the GnRHa triptorelin is associated with high regression rates to normal endometrium, and the presence ofAtypia seems to be a poor prognostic factor.
Successes and failures of uterine leiomyoma drug discovery
TLDR
This systematic review covers the successes and failures of prominent drugs that have been researched for UFs in the past and agents that have shown promise in recent clinical trials, and outlines the direction UF drug discovery is heading.
Differential effect of gonadotropin-releasing hormone analogue treatment on estrogen levels and sulfatase activity in uterine leiomyoma and myometrium.
Treatment of symptomatic uterine leiomyoma with letrozole.
Clinical efficacy of goserelin (Zoladex) in the treatment of uterine myomas in infertile patients.
TLDR
Serum concentrations of follicle stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2) were followed-up before and during Zoladex therapy where multivariate variance analysis showed statistically significant differences.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 47 REFERENCES
Fibroid and myometrial steroid receptors in women treated with gonadotropin-releasing hormone agonist leuprolide acetate.
The histopathology of uterine leiomyomas following treatment with gonadotropin-releasing hormone analogues.
Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot.
Pre-operative gonadotrophin-releasing hormone agonist treatment in surgery for uterine leiomyomata.
TLDR
Pre-operative treatment with GnRH-agonists which induces shrinkage of the uterus and fibroids is efficient in shortening the duration of surgery, and diminishing the intra-operative blood loss in surgery for fibroid uteri.
Efficacy of a low-dose leuprolide acetate depot in the treatment of uterine leiomyomata in Japanese women.
Sequential gonadotrophin-releasing hormone agonist/low-dose oral contraceptive treatment for leiomyomata uteri.
TLDR
Sequential GnRHa/low-dose oral contraceptive treatment is not a useful tool for leiomyomata uteri in perimenopausal women with uterine fibroids.
Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonist * †
Steroid receptor binding and messenger RNA expression in fibroids from untreated and gonadotrophin‐releasing hormone agonist pretreated women
TLDR
It is found that a lack of oestrogen may be the reason for gonadotrophin‐releasing hormone agonist (GnRHa) induced fibroid shrinkage and the mRNA expression of ER and PR in fibroids and myometrium in untreated women and pretreated women was evaluated.
A conservative approach to the management of uterine leiomyoma: pituitary desensitization by a luteinizing hormone-releasing hormone analogue.
Utilization of luteinizing hormone-releasing hormone agonist in pulmonary leiomyomatosis.
...
1
2
3
4
5
...